Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis

General Hospital Psychiatry

Volumn 29, Issue 3, 2007, Pages 281-282

  Peritogiannis, Vaios ^a   Pappas, Dimitrios ^a   Antoniou, Katerina ^b   Hyphantis, Thomas ^a   Mavreas, Venetsanos ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; RIFAMPICIN;

ADULT; AUDITORY HALLUCINATION; CASE REPORT; COUGHING; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; HYPERSALIVATION; LETTER; LEUKOCYTOSIS; LUNG TUBERCULOSIS; MALE; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PERSECUTORY DELUSION; SEDATION; SIDE EFFECT; SUICIDE ATTEMPT;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG INTERACTIONS; HUMANS; MALE; RIFAMPIN; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 34247581340     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2007.02.004     Document Type: Letter

References (13)

1. Spina E., Scordo M., and D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17 (2003) 517-538
2. Spina E., and de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100 (2007) 4-22
3. Linnet K., and Olesen O. Metabolism of clozapine by DNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 25 (1997) 1379-1382
4. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 171 (1997) 109-112
5. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 22 (1992) 47-65
6. Borcherding S.M., Baciewicz A.M., and Self T.H. Update on rifampin drug interactions. II. Arch Intern Med 152 (1992) 711-716
7. Wietholtz H., Zysset T., Marschall H., Generet K., and Matuns S. The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 22 (1995) 78-81
8. Niemi M., Backman J., Fromm M., Neuvonen P., and Kivisto K. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42 (2003) 819-850
9. Joos A., Frank U., and Kaschka W. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with atypical mycobacterial infection. (letter). J Clin Psychopharmacol 18 (1998) 83-85
10. Backman J., Granfors M., and Neuvonen P. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62 (2006) 451-461
11. Prior T., and Baker G. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28 (2003) 99-112
12. Kim Y.H., Cha I.J., Shim J.C., Shin J.G., Yoon Y.R., Kim Y.K., et al. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administrated to schizophrenic patients. J Clin Psychopharmacol 16 (1996) 247-252
13. Dye C., Watt C., Bleed D., Hosseini S., and Raviglione M. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence and deaths globally. JAMA 293 (2005) 2790-2793